148 related articles for article (PubMed ID: 35027056)
1. Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues.
Lu J; Zhao M; Wu C; Chu C; Zhang CZ; Cao Y
Diagn Pathol; 2022 Jan; 17(1):10. PubMed ID: 35027056
[TBL] [Abstract][Full Text] [Related]
2. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
3. Detection of HPV infection in urothelial carcinoma using RNAscope: Clinicopathological characterization.
Musangile FY; Matsuzaki I; Okodo M; Shirasaki A; Mikasa Y; Iwamoto R; Takahashi Y; Kojima F; Murata SI
Cancer Med; 2021 Aug; 10(16):5534-5544. PubMed ID: 34164940
[TBL] [Abstract][Full Text] [Related]
4. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
Gailey MP; Bellizzi AM
Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
[TBL] [Abstract][Full Text] [Related]
6. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
7. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
8. Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma.
Vlajnic T; Chijioke O; Roma L; Savic Prince S; Zellweger T; Rentsch CA; Bubendorf L
Mod Pathol; 2024 Jun; 37(6):100495. PubMed ID: 38641323
[TBL] [Abstract][Full Text] [Related]
9. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
10. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of GATA-3 in urothelial carcinoma variants.
Liang Y; Heitzman J; Kamat AM; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2014 Jul; 45(7):1466-72. PubMed ID: 24745616
[TBL] [Abstract][Full Text] [Related]
12. CD138 Expression Is Observed in the Urothelial Epithelium and in Various Urothelial Carcinomas, and Cannot Be Evidence for Plasmacytoid Urothelial Carcinoma.
Goto K
Int J Surg Pathol; 2016 Oct; 24(7):614-9. PubMed ID: 27305940
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-11 as a marker of metastasis and predictor of poor survival in urothelial carcinomas.
Li WM; Wei YC; Huang CN; Ke HL; Li CC; Yeh HC; Chang LL; Huang CH; Li CF; Wu WJ
J Surg Oncol; 2016 May; 113(6):700-7. PubMed ID: 26861489
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
15. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
Gulinac M; Dikov D; Velikova T; Belovezhdov V
Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
[TBL] [Abstract][Full Text] [Related]
16. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
17. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].
Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor α (ERα) status evaluation using RNAscope in situ hybridization: a reliable and complementary method for IHC in breast cancer tissues.
Yu X; Guo S; Song W; Xiang T; Yang C; Tao K; Zhou L; Cao Y; Liu S
Hum Pathol; 2017 Mar; 61():121-129. PubMed ID: 27993577
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center.
McIntire P; Khan R; Kilic I; Wojcik EM; Pambuccian SE; Barkan GA
Ann Diagn Pathol; 2019 Aug; 41():124-128. PubMed ID: 31238192
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
